Project Grant W81XWH2110240

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

The Department of the Army Medical Command awarded a $1,210,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Mayo Clinic to conduct research exploring novel biomarkers for amyotrophic lateral sclerosis (ALS). The 3-year grant, titled "Exploring Novel ALS Biomarkers: Multiomics Approach Utilizing Immunoprofiling, Extracellular Vesicle Analysis, and TDP-43 Aggregation Assays," aims to advance the understanding of ALS pathogenesis and identify...

This federal Project Grant award of $704,431.23 from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to Meso Scale Diagnostics LLC, doing business as Meso Scale Discovery, supports the development of ultrasensitive plasma and cerebrospinal fluid immunoassays to enable clinical trials for amyotrophic lateral sclerosis (ALS). As a for-profit limited liability company specializing in assay development, laboratory testing, and related products for biomedical...

This Project Grant award, valued at $1,106,142 and effective September 1, 2024 through July 31, 2029, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The primary objective is to identify mechanisms of neurofilament regulation and turnover in amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disorder. Key activities...

This $427,625 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the University of Washington aims to develop and optimize two novel blood-based biomarker assays to improve clinical diagnosis and differential diagnosis of Parkinson's disease (PD) and multiple system atrophy (MSA). The key products and services to be delivered under this 2-year grant include: Further development and optimization of a flow cytometry-based assay (APOGEE) to directly quantify...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $227,205 to Cedars-Sinai Medical Center to conduct research aimed at identifying pathological signatures and molecular markers in the motor cortex of patients with amyotrophic lateral sclerosis (ALS). The key objectives are to: 1) use advanced MRI techniques to correlate in vivo...

This $140,314 National Science Foundation project grant under the Integrative Activities program (CFDA 47.083) will fund research and training related to exosome proteomics analysis and biomarker discovery for cancer diagnostics. Louisiana Tech University will collaborate with the University of Houston to identify glioblastoma-specific protein biomarkers in exosomes purified from biofluids using disease-specific surface markers. The Principal Investigator and one graduate student will receive...

The Department of the Army Medical Command awarded a $1,181,251 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the University of California, Los Angeles (UCLA) for the project "NEURONAL EXOSOME-BASED BIOMARKERS FOR ALS DIAGNOSIS AND DISEASE PROGRESSION". The grant, with a performance period from April 15, 2025 to April 14, 2028, supports advanced biomedical research focused on transforming healthcare for military service members and the...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Trustees of Columbia University in the City of New York provides $452,375 to investigate the potential use of the APLP1 protein as an early biomarker for Alzheimer's disease in individuals with Down syndrome. The project aims to leverage recent findings linking endosomal trafficking defects to the early pathology of Alzheimer's disease, which is observed decades before classical...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...